Eli Lilly and Company (NYSE:LLY) Stock Holdings Decreased by Kentucky Retirement Systems Insurance Trust Fund

Kentucky Retirement Systems Insurance Trust Fund lessened its stake in Eli Lilly and Company (NYSE:LLY) by 9.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,356 shares of the company’s stock after selling 2,394 shares during the quarter. Eli Lilly and Company makes up approximately 1.4% of Kentucky Retirement Systems Insurance Trust Fund’s holdings, making the stock its 11th biggest holding. Kentucky Retirement Systems Insurance Trust Fund’s holdings in Eli Lilly and Company were worth $20,692,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Vawter Financial Ltd. raised its stake in Eli Lilly and Company by 5.7% during the third quarter. Vawter Financial Ltd. now owns 1,861 shares of the company’s stock valued at $1,649,000 after buying an additional 100 shares in the last quarter. First Long Island Investors LLC lifted its stake in Eli Lilly and Company by 1.8% during the third quarter. First Long Island Investors LLC now owns 19,130 shares of the company’s stock worth $16,948,000 after purchasing an additional 346 shares during the last quarter. Simplify Asset Management Inc. boosted its holdings in Eli Lilly and Company by 67.2% in the third quarter. Simplify Asset Management Inc. now owns 19,082 shares of the company’s stock worth $16,906,000 after purchasing an additional 7,670 shares during the period. Altrius Capital Management Inc increased its stake in Eli Lilly and Company by 1.0% during the third quarter. Altrius Capital Management Inc now owns 1,285 shares of the company’s stock valued at $1,138,000 after purchasing an additional 13 shares during the last quarter. Finally, KCM Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 1.0% during the third quarter. KCM Investment Advisors LLC now owns 38,668 shares of the company’s stock worth $34,258,000 after purchasing an additional 394 shares during the period. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on LLY shares. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Barclays decreased their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Finally, BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 5.0 %

Shares of LLY opened at $745.89 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a 50 day simple moving average of $882.65 and a 200-day simple moving average of $869.77. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The stock has a market cap of $708.09 billion, a PE ratio of 80.64, a PEG ratio of 3.07 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the company earned $0.10 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.